Clinical trials
Semaglutide clinical trials
Below are recruiting semaglutide clinical trials, each written for real people, not researchers. We’re tracking 139 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07297589RecruitingPhase 3
CT scan of heart fat after heart attack
This study uses a CT scan to look at the layer of fat around the heart in people who recently had a heart attack and have type 2 diabetes and obesity. It aims to understand how this fat relates to inflammation and heart health.
León, GuanajuatoAges 18 years+ - NCT07295223RecruitingPhase 3
GLP-1 and SGLT2 drugs for heart attack recovery
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
León, GuanajuatoAges 18 years+ - NCT07280221Enrolling by invitation
Wegovy real-world weight loss study in Korea
This study tracks how well Wegovy (a once-weekly injection for weight loss) works for people in Korea who are just starting the medication. It helps doctors understand real-world results outside of a research clinic.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT07275697RecruitingPhase 4
Weight loss drug and heart ablation study for AFib
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
StockholmAges 18 years+ - NCT07254572RecruitingPhase 4
Comparing diabetes drugs for heart health in prediabetes
This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.
WarsawAges 18–80 - NCT07239570RecruitingPhase 4
Using biomarkers to personalize kidney disease treatment
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
HerlevAges 18–75 - NCT07218354RecruitingPhase 3
Study of semaglutide to help veterans drink less alcohol
This study tests whether a weekly medicine called semaglutide can help veterans who drink heavily reduce their alcohol intake. If you're a veteran and want to cut down on drinking, this study may be an option.
Long Beach, CaliforniaAges 18–80 - NCT07213466RecruitingPhase 4
Personalized weight-loss medication for bipolar disorder
This study wants to see if a personalized approach with FDA-approved weight-loss medications can help people with bipolar disorder who are overweight or have obesity, while staying on their mood stabilizer treatment. It might be a good fit if you have bipolar disorder and struggle with your weight.
Rochester, MinnesotaAges 18–65 - NCT07221214RecruitingPhase 2
Testing a diabetes drug for drinking and heart health in HIV
This trial tests if a once-weekly diabetes medication (semaglutide) can help people with HIV reduce heavy drinking and improve heart health. It's for people who drink alcohol and have a higher body weight.
Nashville, TennesseeAges 18–89 - NCT07204249RecruitingPhase 2
Testing a diabetes drug to help stop meth use
This study tests whether a medication called 'Glutide' (a GLP-1 agonist, similar to drugs used for diabetes) can help people who want to stop or cut down on methamphetamine. It's for those with moderate to severe meth use disorder who have used meth on at least 15 of the past 30 days.
San Francisco, CaliforniaAges 18–65 - NCT07202247RecruitingPhase 2
Improving heart health in prostate cancer patients on hormone therapy
This study tests whether combining a time-restricted eating plan, a heart-healthy diet, and a weight-loss medication (GLP-1 receptor agonist) can help improve heart health and weight in men with prostate cancer who are receiving hormone therapy. It aims to reduce the risk of heart problems caused by hormone treatment.
Duarte, CaliforniaAges 30–79 - NCT07187830Recruiting
Semaglutide for belly fat and liver health in kidney disease
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
Edmonton, AlbertaAges 18 years+ - NCT07154238Enrolling by invitation
Semaglutide for weight management: a real-world study
This study looks at the experiences of people using injectable semaglutide for weight loss, as well as the doctors who prescribe it. It aims to understand how the treatment works in everyday life.
Bad OeynhausenAges 18 years+ - NCT07091500Recruiting
Exercise and a weight-loss drug for people with obesity
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
St Louis, MissouriAges 50–75 - NCT07055607Enrolling by invitation
Real-world study of Wegovy for weight management
This study observes how Wegovy works in everyday medical practice for people who are starting it for the first time. It will help doctors learn more about its real-life benefits and safety.
BarcelonaAges 18 years+ - NCT07057310Enrolling by invitationPhase 4
Weight Loss Drug for Postmenopausal Women With Obesity
This study tests a GLP-1 agonist medication (like Ozempic) to help postmenopausal women lose weight and improve physical and blood vessel health. It focuses on women aged 46–60 with obesity.
Jacksonville, FloridaAges 46–60 - NCT07036172RecruitingPhase 3
Semaglutide vs Wegovy for weight loss in Chinese adults
This trial compares a semaglutide injection to the already-approved weight loss drug Wegovy in Chinese adults with obesity. It aims to see if the new option works just as well to help people lose weight.
BeijingAges 18–75 - NCT07017270RecruitingPhase 4
GLP-1 drugs for people with diabetes on dialysis
This study tests if a type 2 diabetes medication called a GLP-1 receptor agonist (like Ozempic) is safe and effective for people on dialysis. It may help manage blood sugar and improve health outcomes for those with kidney failure.
Toronto, OntarioAges 18 years+ - NCT06989203Recruiting
Protein supplement study for body weight
This trial tests how protein supplements affect body weight in people who are either normal weight or overweight. The goal is to see if adding protein helps with weight management.
Hangzhou, ZhejiangAges 20–50 - NCT06989177Recruiting
Can a probiotic help with body weight?
This trial tests whether taking a probiotic (a good bacteria supplement) can help with body weight. It is for healthy adults, and also for overweight or obese people who have certain weight-related health issues.
Hangzhou, ZhejiangAges 20–50 - NCT06975111RecruitingPhase 2/Phase 3
Improving health during menopause
This trial studies ways to help women during the late menopausal transition. It uses a smartphone app and telehealth visits to track your health and help you feel better.
Aurora, ColoradoAges 45–55 - NCT06959784Enrolling by invitationPhase 4
A study on new diabetes drugs for heart health and remission
This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.
BeijingAges 30–70 - NCT06954090Enrolling by invitationPhase 4
Urine test to guide early treatment in type 2 diabetes
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
Herlev, Hajdú-BiharAges 18 years+ - NCT06897475RecruitingPhase 2
Study of LY3457263 for type 2 diabetes on semaglutide or tirzepatide
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
Phoenix, ArizonaAges 18–75
Hear when a new Semaglutide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for semaglutide?
- Yes. Clin2 currently lists 139 recruiting semaglutide studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a semaglutide trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a semaglutide trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.